Sugi Predict

Sugi Predict / Compounds / SCHEMBL17683271

SCHEMBL17683271

SCHEMBL17683271

CCOC(=O)n1nc(O)c2cc(Cl)ccc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ELANE P08246 3/20 0.52
▸ ALDH1A1 P00352 3/20 0.48
▸ LMNA P02545 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ KDM4E B2RXH2 4/20 0.47
▸ HPGD P15428 1/20 0.47
▸ ALOX15 P16050 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ CASP1 P29466 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ MAPK8 P45983 3/20 0.45
▸ TP53 P04637 1/20 0.44
▸ ADORA3 P0DMS8 1/20 0.41
▸ MAPK9 P45984 1/20 0.41
▸ MAPK10 P53779 1/20 0.41
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ MAOB P27338 1/20 0.40
▸ IDE P14735 1/20 0.40
▸ MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11755931 0.85 ELANE (0.51) ELANEALDH1A1LMNAL3MBTL1KDM4E
SCHEMBL19210227 0.84 ELANE (0.50) ELANEALDH1A1LMNAL3MBTL1KDM4E
SCHEMBL2304878 0.83 ELANE (0.55) ELANEALDH1A1LMNAMAPK8MAPT
SCHEMBL19532532 0.81 ELANE (0.40) ELANEKDM4EMAPK8MAPK9MAPT
SCHEMBL2671559 0.80 KDM4E (0.50) ELANEKDM4ENPC1
SCHEMBL5120296 0.80 ELANE (0.56) ELANEALDH1A1KDM4E
SCHEMBL28284215 0.79 KDM4E (0.40) ELANEALDH1A1KDM4EMAPK8MAPK9
SCHEMBL15081336 0.79 ELANE (0.58) ELANEALDH1A1LMNAMAPT
SCHEMBL11751308 0.77 ADORA2A (0.49) ELANEALDH1A1LMNAL3MBTL1KDM4E
SCHEMBL2304978 0.75 TYRO3 (0.48) ELANEALDH1A1LMNAMAPK8MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117402143-A EGFR inhibitor and preparation and application thereof 上海翰森生物医药科技有限公司 2024-01-16 — — CN disclosed
CN-117069700-A EGFR inhibitor and preparation and application thereof 上海翰森生物医药科技有限公司 2023-11-17 — — CN disclosed
CN-117050062-A EGFR inhibitor and preparation and application thereof 上海翰森生物医药科技有限公司 2023-11-14 — — CN disclosed
CN-111187221-B EGFR inhibitor and preparation and application thereof 上海翰森生物医药科技有限公司 2023-09-26 — — CN disclosed
CN-111171000-B EGFR inhibitor and preparation and application thereof 上海翰森生物医药科技有限公司 2023-09-01 — — CN disclosed
CN-111170999-B EGFR inhibitor and preparation and application thereof 上海翰森生物医药科技有限公司 2023-06-30 — — CN disclosed
EP-3205650-B1 EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) 2021-08-04 — — EP disclosed
EP-3205650-B1 EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) 2021-08-04 — — EP disclosed
CN-111187221-A EGFR inhibitor and preparation and application thereof 上海翰森生物医药科技有限公司 2020-05-22 — — CN disclosed
CN-111170999-A EGFR inhibitor and preparation and application thereof 上海翰森生物医药科技有限公司 2020-05-19 — — CN disclosed
US-10259820-B2 EGFR inhibitor, preparation method and use thereof SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2019-04-16 — — US disclosed
CN-106661000-B EGFR inhibitor and preparation and application thereof 上海翰森生物医药科技有限公司 2019-04-09 — — CN disclosed
US-20190100528-A1 EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2019-04-04 — — US disclosed
US-20190100528-A1 EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2019-04-04 — — US disclosed
US-20170313714-A1 EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2017-11-02 — — US disclosed
US-20170313714-A1 EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2017-11-02 — — US disclosed
EP-3205650-A1 EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2017-08-16 — — EP disclosed
EP-3205650-A1 EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2017-08-16 — — EP disclosed
CN-106661000-A EGFR inhibitor and preparation and application thereof 上海翰森生物医药科技有限公司 2017-05-10 — — CN disclosed
WO-2016054987-A1 EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF 上海翰森生物医药科技有限公司 2016-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170313714-A1 EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF EGFR, ERBB2, ERBB4 ELANE 3025/4885ALDH1A1 2036/4885LMNA 2264/4885
US-20190100528-A1 EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF EGFR, ERBB2, ERBB4 ELANE 2790/4885ALDH1A1 2919/4885LMNA 1857/4885
US-10259820-B2 EGFR inhibitor, preparation method and use thereof EGFR, ERBB2, ERBB4 ELANE 3025/4885ALDH1A1 2036/4885LMNA 2264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.